Overview

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Status:
Completed
Trial end date:
2001-05-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy with may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of chemotherapy with vinorelbine and paclitaxel plus radiation therapy in treating patients with advanced cancer arising in the pelvis.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Vinblastine
Vinorelbine
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed locally advanced carcinoma of the uterine
cervix, vagina, or bladder or other pelvic malignancy for which whole pelvic radiation
therapy is planned Metastatic disease is permitted

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: CALGB 0-2 Hematopoietic: WBC at
least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin within normal limits
Renal: Creatinine no greater than 2.5 mg/dL Cardiovascular: No unstable angina or
myocardial infarction in previous 6 months Other: Not pregnant No significant concomitant
illness, uncontrolled infection, or cirrhosis

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior whole pelvic radiation
therapy Surgery: Not specified